Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131627 | 0.89 | EPHX1 (0.59) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL2807429 | 0.86 | EPHX1 (0.49) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL2807431 | 0.86 | EPHX1 (0.49) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| Acetic Acid SCHEMBL2808744 | 0.84 | EPHX1 (0.45) | EPHX1EPHX2KDM1AALDH1A1KDM5A | |
| Acetic Acid SCHEMBL2808743 | 0.84 | EPHX1 (0.45) | EPHX1EPHX2KDM1AALDH1A1KDM5A | |
| SCHEMBL2828768 | 0.81 | EPHX1 (0.45) | EPHX1EPHX2KDM1ACYP2C19PARP1 | |
| SCHEMBL13638962 | 0.81 | EPHX1 (0.47) | EPHX1EPHX2KDM1ACYP2C19ALDH1A1 | |
| SCHEMBL13162268 | 0.81 | EPHX1 (0.47) | EPHX1EPHX2KDM1ACYP2C19ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2772564 | 0.79 | EPHX1 (0.46) | EPHX1EPHX2KDM1ACYP2C19ALDH1A1 | |
| SCHEMBL13999540 | 0.79 | HSD11B1 (0.57) | EPHX1PARP1HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306123-A1 | NOVEL COMPOUNDS | PFIZER INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1638933-B1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LTD (GB) | 2008-06-11 | — | — | EP | disclosed |
| US-7378436-B2 | Compounds | PFIZER INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | EPHX1 259/4885EPHX2 549/4885KDM1A 2249/4885 |
| US-20080306123-A1 | NOVEL COMPOUNDS | ADRB3, HTR3A, HTR3C | EPHX1 124/4885EPHX2 263/4885KDM1A 2709/4885 |
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | EPHX1 1834/4885EPHX2 1291/4885KDM1A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.